Biotech Voices

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Our contributors are not paid for their opinions.

Have any questions or feedback, or think you have a voice that should be heard? Reach out to Amber Tong.

Biotech Voices

Biotech voices channel feed

Guest col­umn: What hap­pened with Es­pe­ri­on — and what de­fines suc­cess or fail­ure?

5 weeks ago

6 key clin­i­cal tri­al trends that we should em­brace and build on

8 months ago

8 ways Chi­na could help trans­form the glob­al bio­phar­ma in­dus­try

9 months ago

Ad­u­canum­ab has its ap­proval — now, let cit­i­zen-sci­en­tists come to­geth­er to see if it works

10 months ago

RNA: From the mes­sen­ger to the med­i­cine

11 months ago

The right to vote is fun­da­men­tal — a let­ter from biotech­nol­o­gy in­dus­try lead­ers

Last year
People

The con­tin­u­ing CRISPR patent saga

Last year

In­no­va­tion in the clin­ic is pick­ing up steam. How adap­tive de­signs could pave the road to per­son­al­ized med­i­cine

Last year

How we are stay­ing con­nect­ed when we’re apart

Last year

The path to NASH: un­der­stand­ing the role of se­vere obe­si­ty in a com­plex, mul­ti-sys­tem dis­ease

Last year

In­dus­try lead­ers need to speak out now more than ever

Last year

Why mu­cos­al im­mu­ni­ty may be re­quired to end the pan­dem­ic

Last year

How will the Biden ad­min­is­tra­tion af­fect fund­ing for life sci­ence re­search?

Last year

Re­vis­it­ing the 'cy­tokine stor­m' in ARDS; the painful wait for an­ti-in­flam­ma­to­ry drugs/tar­gets that solve Covid-19 deaths

Last year

We’re poised for a new era of med­ical ad­vances. A key step: un­der­stand­ing the mol­e­c­u­lar ma­chines that gov­ern health and dis­ease

Last year

Next-gen ther­a­pies are evolv­ing fast. The drug de­vel­op­ment mod­el needs to keep up

Last year

Bio­science in­dus­try stake­hold­er col­lab­o­ra­tion key to ad­dress­ing in­equal­i­ty

Last year

Biotech Voic­es: Coro­n­avirus will change biotech re­search with re­mote col­lab­o­ra­tions

Last year
Coronavirus

Two years in, Hong Kong’s biotech ex­per­i­ment has been val­i­dat­ed

Last year
Financing
China

Drug dis­cov­ery in the age of coro­n­avirus

3 years ago
Coronavirus

Bio­phar­ma has aban­doned an­tibi­ot­ic de­vel­op­ment. Here’s why we did, too.

3 years ago

Biotech boards bur­dened: Bridg­ing the suc­cess gap

3 years ago
Financing
Startups

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

3 years ago
China

Analy­sis: In most of the Big Phar­ma world, R&D spend­ing tow­ers over rev­enue from new drugs. Guess who beat the odds

3 years ago
R&D
Pharma
12 Next page Last page